Next Article in Journal
A DNA Vaccine Encoding SA-4-1BBL Fused to HPV-16 E7 Antigen Has Prophylactic and Therapeutic Efficacy in a Cervical Cancer Mouse Model
Next Article in Special Issue
Thrombin Generation and Cancer: Contributors and Consequences
Previous Article in Journal
Circulating Tumor Cells Develop Resistance to TRAIL-Induced Apoptosis Through Autophagic Removal of Death Receptor 5: Evidence from an In Vitro Model
Previous Article in Special Issue
Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges
Review

Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models

1
Interinstitutional Multidisciplinary Biobank, IRCCS San Raffaele Pisana, 00166 Rome, Italy
2
Department of Systems Medicine, Medical Oncology, University of Rome Tor Vergata, 00133 Rome, Italy
3
Department of Human Sciences & Quality of Life Promotion, San Raffaele Roma Open University, 00166 Rome, Italy
4
Department of Enterprise Engineering, University of Rome “Tor Vergata”, 00133 Rome, Italy
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(1), 95; https://doi.org/10.3390/cancers11010095
Received: 14 November 2018 / Revised: 7 December 2018 / Accepted: 8 January 2019 / Published: 15 January 2019
(This article belongs to the Special Issue The Role of Thrombosis and Haemostasis in Cancer)
Risk prediction of chemotherapy-associated venous thromboembolism (VTE) is a compelling challenge in contemporary oncology, as VTE may result in treatment delays, impaired quality of life, and increased mortality. Current guidelines do not recommend thromboprophylaxis for primary prevention, but assessment of the patient’s individual risk of VTE prior to chemotherapy is generally advocated. In recent years, efforts have been devoted to building accurate predictive tools for VTE risk assessment in cancer patients. This review focuses on candidate biomarkers and prediction models currently under investigation, considering their advantages and disadvantages, and discussing their diagnostic performance and potential pitfalls. View Full-Text
Keywords: venous thromboembolism; biomarkers; clinical decision systems; risk assessment models; machine learning venous thromboembolism; biomarkers; clinical decision systems; risk assessment models; machine learning
Show Figures

Figure 1

MDPI and ACS Style

Riondino, S.; Ferroni, P.; Zanzotto, F.M.; Roselli, M.; Guadagni, F. Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers 2019, 11, 95. https://doi.org/10.3390/cancers11010095

AMA Style

Riondino S, Ferroni P, Zanzotto FM, Roselli M, Guadagni F. Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers. 2019; 11(1):95. https://doi.org/10.3390/cancers11010095

Chicago/Turabian Style

Riondino, Silvia, Patrizia Ferroni, Fabio M. Zanzotto, Mario Roselli, and Fiorella Guadagni. 2019. "Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models" Cancers 11, no. 1: 95. https://doi.org/10.3390/cancers11010095

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop